Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
IS11 - Satellite CME Symposium by Medscape: Answers to Key Questions About Molecular Alterations Within NSCLC: How Do You Stack Up?
- 21:15 - 22:15
- 9/12/2021
- Location: Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track: N.A.
-
+
IS11.01 - Introduction
21:15 - 21:15 | Presenter: Zofia Piotrowska
- Abstract
No abstract available for this presentation
-
+
IS11.02 - Key Questions for Practice: Optimizing the Diagnosis and Management of Patients with NSCLC and Molecular Alterations
21:15 - 21:15 | Presenter: Zofia Piotrowska, Joshua Sabari, Maureen Zakowski
- Abstract
No abstract available for this presentation
-
+
IS11.03 - Conclusions and Q&A
21:15 - 21:15 | Presenter: Zofia Piotrowska
- Abstract
No abstract available for this presentation
-
+
IS11.04 - Backstage Pass Breakout Session (Optional)
21:15 - 21:15
- Abstract
No abstract available for this presentation
-
+
IS12 - Satellite CME Symposium by Research To Practice: Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Early-Stage Non-Small Cell Lung Cancer
- 21:15 - 22:15
- 9/12/2021
- Location: Program Auditorium
- CME Accredited by Other Provider
- Type: Satellite CME Symposia
- Track: N.A.
-
+
IS12.01 - Established Management Paradigm for Early-Stage Non-Small Cell Lung Cancer (NSCLC)
21:15 - 21:35
- Abstract
No abstract available for this presentation
-
+
IS12.02 - Emerging Role of Immune Checkpoint Inhibitors as Neoadjuvant or Adjuvant Therapy for Localized NSCLC
21:35 - 21:55
- Abstract
No abstract available for this presentation
-
+
IS12.03 - Optimal Approaches to the Monitoring and Management of Toxicities in Patients Receiving Neoadjuvant or Adjuvant Anti-PD-1/PD-L1 Antibody Therapy
21:55 - 22:15
- Abstract
No abstract available for this presentation
-
+
IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies
- 16:15 - 17:15
- 9/13/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS14.01 - Disease Landscape Overview
16:15 - 16:30 | Presenter: Luis Paz-Ares
- Abstract
No abstract available for this presentation
-
+
IS14.02 - Pathobiology and Molecular Profile of ADC Targets in NSCLC
16:30 - 16:40 | Presenter: Corey Langer
- Abstract
No abstract available for this presentation
-
+
IS14.03 - ADCs Targeting the HER Family and Clinical Data in NSCLC
16:40 - 16:50 | Presenter: Keunchil Park
- Abstract
No abstract available for this presentation
-
+
IS14.04 - Emerging ADC Targets and Clinical Data in NSCLC
16:50 - 17:00 | Presenter: Marina Chiara Garassino
- Abstract
No abstract available for this presentation
-
+
IS14.05 - Faculty Panel: Live Q&A
17:00 - 17:15
- Abstract
No abstract available for this presentation
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
17:30 - 17:35 | Presenter: Shengxiang (Harry) Ren
- Abstract
Loading... -
+
MA13.02 - Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer
17:35 - 17:40 | Presenter: Sonam Puri
- Abstract
Loading... -
+
MA13.03 - Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial
17:40 - 17:45 | Presenter: Jiyun Lee
- Abstract
Loading... -
+
MA13.04 - Discussant
17:45 - 17:55 | Presenter: Alessandra Curioni-Fontecedro
- Abstract
No abstract available for this presentation
-
+
MA13.05 - Prognostic Impact of Immune Related Adverse Events in Advanced Non-Small Cell Lung Cancer Patients with ICIs Treatment
17:55 - 18:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
MA13.06 - Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy
18:00 - 18:05 | Presenter: Benedict James Girling
- Abstract
Loading... -
+
MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC
18:05 - 18:10 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
18:10 - 18:15 | Presenter: Jie Wang
- Abstract
Loading... -
+
MA13.09 - Discussant
18:15 - 18:30 | Presenter: Keunchil Park
- Abstract
No abstract available for this presentation
-
+
OA18 - Real World Data in a Modern World
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Global Health
- Moderators:Massimo Di Maio
-
+
OA18.01 - Lung Cancer in Vietnam
17:30 - 17:40 | Presenter: Sang Nguyen
- Abstract
Loading... -
+
OA18.02 - Canprim Beyond Oncology Into Primary Care Cancer Distress Follow-up Study Among Outpatients
17:40 - 17:50 | Presenter: Aissa Gabriela Suciu
- Abstract
Loading... -
+
OA18.03 - LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors - Multicenter Observational Study in Portugal
17:50 - 18:00 | Presenter: Denise Magalhães
- Abstract
Loading... -
+
OA18.04 - Discussant
18:00 - 18:10 | Presenter: Bill Mayfield
- Abstract
No abstract available for this presentation
-
+
OA18.05 - Live Discussion with Speakers
18:10 - 18:30
- Abstract
No abstract available for this presentation
-
+
OA19 - Screening and Early Detection: State of the Art
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Screening and Early Detection
- Moderators:John K Field
-
+
OA19.01 - Prospective Study of Lung Cancer Screening Criteria: USPSTF2013 vs PLCOm2012 – International Lung Screening Trial (ILST) Results
17:30 - 17:40 | Presenter: Martin C Tammemagi
- Abstract
Loading... -
+
OA19.02 - The UKLS Trial Outcome Results: Lung Cancer Mortality Reduction by LDCT Screening Confirmed in an International Meta-Analysis
17:40 - 17:50 | Presenter: John K Field
- Abstract
Loading... -
+
OA19.03 - Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-Dose CT Screening
17:50 - 18:00 | Presenter: Yeon Wook Kim
- Abstract
Loading... -
+
OA19.04 - Potential Clinical and Economic Impact of Missed Lung Nodules – A Claims Database Analysis
18:00 - 18:10 | Presenter: Fernando J Suarez Saiz
- Abstract
Loading... -
+
OA19.05 - Discussant
18:10 - 18:20 | Presenter: Annette Maree McWilliams
- Abstract
No abstract available for this presentation
-
+
OA19.06 - Live Discussion with Speakers
18:20 - 18:30
- Abstract
No abstract available for this presentation
-
+
MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
MA14.01 - Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer
18:45 - 18:50 | Presenter: Sai-Hong I. Ou
- Abstract
Loading... -
+
MA14.02 - RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
18:50 - 18:55 | Presenter: Fernando Lopez-Rios
- Abstract
Loading... -
+
MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib
18:55 - 19:00 | Presenter: Ferdinandos Skoulidis
- Abstract
Loading... -
+
MA14.04 - Discussant
19:00 - 19:15 | Presenter: Umberto Mallapelle
- Abstract
No abstract available for this presentation
-
+
MA14.05 - Clinicopathologic and Genomic Significances of the Amount of High-Grade Histologic Components in Lung Adenocarcinoma
19:15 - 19:20 | Presenter: Bokyung Ahn
- Abstract
Loading... -
+
MA14.06 - High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
19:20 - 19:25 | Presenter: Seung Hyeun Lee
- Abstract
Loading... -
+
MA14.07 - EGFR-Mutant NSCLC With de novo or Acquired Squamous Histology: Molecular Features and Clinical Outcomes
19:25 - 19:30 | Presenter: Catherine Belle Meador
- Abstract
Loading... -
+
MA14.08 - Discussant
19:30 - 19:45 | Presenter: Lukas Bubendorf
- Abstract
No abstract available for this presentation
-
+
MA15 - Real World Factors Affecting Lung Cancer Outcomes
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Health Services Research/Health Economics
-
+
MA15.01 - Machine Learning for Prediction of Survival and Risk of Mortality in Patients with Lung Cancer Undergoing Resection
18:45 - 18:50 | Presenter: Renata Matheus Faccioli
- Abstract
Loading... -
+
MA15.02 - Association of Healthcare System Resources With Lung Cancer Screening Utilization
18:50 - 18:55 | Presenter: Jennifer A. Lewis
- Abstract
Loading... -
+
MA15.03 - Social Factors Influencing the Length of Stay in Hospital After Anatomical Resection
18:55 - 19:00 | Presenter: Miriam Patella
- Abstract
Loading... -
+
MA15.04 - Discussant
19:00 - 19:15 | Presenter: Dan Raz
- Abstract
No abstract available for this presentation
-
+
MA15.05 - Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)
19:15 - 19:20 | Presenter: Kenneth L Kehl
- Abstract
Loading... -
+
MA15.06 - Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults
19:20 - 19:25 | Presenter: Bonnie Leung
- Abstract
Loading... -
+
MA15.07 - Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age
19:25 - 19:30 | Presenter: Shinkichi Takamori
- Abstract
Loading... -
+
MA15.08 - Discussant
19:30 - 19:45 | Presenter: Andrew G. Robinson
- Abstract
No abstract available for this presentation
-
+
OA20 - Exploring Treatment Modalities and Tools in Locally Advanced NSCLC
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Locally Advanced Non-Small Cell Lung Cancer
- Moderators:Leena Gandhi
-
+
OA20.01 - Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
18:45 - 18:53 | Presenter: Mariano Provencio
- Abstract
Loading... -
+
OA20.02 - Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy
18:53 - 19:01 | Presenter: Atocha Romero
- Abstract
Loading... -
+
OA20.03 - Discussant
19:01 - 19:09 | Presenter: Bruna Pellini
- Abstract
No abstract available for this presentation
-
+
OA20.04 - Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer
19:09 - 19:17 | Presenter: Jorind Beqari
- Abstract
Loading... -
+
OA20.05 - Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer
19:17 - 19:25 | Presenter: Mark Jaradeh
- Abstract
Loading... -
+
OA20.06 - Discussant
19:25 - 19:35 | Presenter: Leah M. Backhus
- Abstract
No abstract available for this presentation
-
+
OA20.07 - Live Discussion with Speakers
19:35 - 19:45
- Abstract
No abstract available for this presentation
-
+
MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies
- 20:00 - 21:00
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Small Cell Lung Cancer/ NET
-
+
MA16.01 - Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
20:00 - 20:05 | Presenter: Vivek Subbiah
- Abstract
Loading... -
+
MA16.02 - Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
20:05 - 20:10 | Presenter: Takashi Sato
- Abstract
Loading... -
+
MA16.03 - CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer
20:10 - 20:15 | Presenter: Alvaro Quintanal-Villalonga
- Abstract
Loading... -
+
MA16.04 - Discussant
20:15 - 20:30 | Presenter: Anish Thomas
- Abstract
No abstract available for this presentation
-
+
MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
20:30 - 20:35 | Presenter: Marina Chiara Garassino
- Abstract
Loading... -
+
MA16.07 - Prognostic Value of 18F-Fluorodeoxyglucose Uptake of Bone Marrow on PET/CT in Patients with Limited Disease Small Cell Lung Cancer
20:35 - 20:40 | Presenter: Merve Ayık Türk
- Abstract
Loading... -
+
MA16.08 - Discussant
20:40 - 20:55 | Presenter: Benjamin Drapkin
- Abstract
No abstract available for this presentation